BNT162 Vaccine [vakcína BNT162]
- Terms
-
abdavomeran
BNT-162a1
BNT-162B1
BNT-162B2
BNT-162C2
BNT162a1
BNT162B1
BNT162B2
BNT162C2
Comirnaty
pidacmeran
tozinameran
tozinameranum
vakcína Pfizer proti COVID-19
vakcína proti COVID-19, Pfizer
vakcína proti COVID-19, Pfizer-BioNTech
-
Abdavomeran
BNT-162A1
BNT-162B1
BNT-162B2
BNT-162C2
BNT162A1
BNT162B1
BNT162B2
BNT162C2
Comirnaty
COVID-19 Vaccine Pfizer-BioNTech
Pfizer Covid-19 Vaccine
Pidacmeran
Tozinameran
mRNA vaccine against SARS-CoV-2 developed by Pfizer and BioNTech.
- DUI
- D000090982 MeSH Browser
- CUI
- M000747629
- History note
- 2022(2021)
- Public note
- 2022; see COVID-19 Vaccines 2021
Allowable subheadings
- AD
- administration & dosage 5
- AE
- adverse effects 7
- AG
- agonists 0
- AA
- analogs & derivatives 0
- AN
- analysis 0
- AI
- antagonists & inhibitors 0
- BI
- biosynthesis 0
- BL
- blood 0
- CF
- cerebrospinal fluid 0
- CS
- chemical synthesis 0
- CH
- chemistry 0
- CL
- classification 0
- EC
- economics 0
- GE
- genetics 0
- HI
- history 0
- IM
- immunology 2
- IP
- isolation & purification 0
- ME
- metabolism 0
- PK
- pharmacokinetics 0
- PD
- pharmacology 2
- PO
- poisoning 0
- RE
- radiation effects 0
- ST
- standards 0
- SD
- supply & distribution 2
- TU
- therapeutic use 0
- TO
- toxicity 0
- UR
- urine 0